Research Projects

Key Initiatives You Can Champion

Donate Now

A Game-Changer in Myeloma Monitoring & Treatment

IMBCR scientists have discovered that the “i1”protein is a key indicator of myeloma progression. Specifically, we have shown that blood levels of this protein are elevated in myeloma patients and can be used to predict outcomes and monitor patients with this disease. We have shown that reducing levels of this protein knocks out myeloma.

Our laboratory has now developed compounds that prevent “i1” from functioning and shown that they eradicate myeloma in our laboratory studies! Our research team has shown that these compounds also help prevent the spread of myeloma and overcome the immune deficiency that is a hallmark of myeloma. We believe we are on the cusp of a revolutionary new therapy for myeloma patients. disease.

Checkpoint JAK inhibitor project

Multiple myeloma (MM) tumor cells evade host immunity through a variety of mechanisms, which may potentially include the PD-L1 and PD-1 axis (see above). This interaction contributes to the immunosuppressive bone marrow microenvironment, ultimately leading to reduced ability of immune cells to eliminate myeloma. We have demonstrated that an already available drug called ruxolitinib that is an inhibitor of JAK proteins reduces PD-L1 expression in the MM bone marrow; this restores immune-mediated elimination of myeloma.

In the clinic, we have demonstrated that this same drug when combined with steroids shows significant clinical benefit for previously treated myeloma patients and this drug can also overcome resistance to a frequently used drug for treating myeloma called lenalidomide.

We are continuing to study a variety of JAK inhibitors alone and combined with other active anti-MM drugs to determine their effects on checkpoint proteins and immune mediated killing.

Serum B-cell Maturation Antigen (sBCMA)

Standard biomarkers for multiple myeloma include measuring blood and urine levels of the monoclonal immunoglobulin that is produced by the malignant plasma cell. These tests include serum protein electrophoresis, quantitative immunoglobulins, and the free light chain assay. Unfortunately, these tests are limited in their usefulness because they can be affected by kidney function and slowly respond to changes in the patient’s clinical status. Also, many patients have nonsecretory multiple myeloma in which these biomarkers are not measurable.

sBCMA test

Our group has identified a new serum marker for following myeloma patients called serum B‑cell maturation antigen (sBCMA). The protein is present on the outside of myeloma cells and is shed into the blood. This protein is easy to measure in the blood using equipment that is currently available in clinical laboratories and is stable at room temperature for weeks making it a very convenient test.

sBCMA in myeloma

We have investigated the use of serum BCMA (sBCMA) for both predicting outcomes and monitoring patients with multiple myeloma and related disorders. The average serum level among myeloma patients prior to starting treatment was more than 10 times higher than the amount found along healthy controls.

We have also investigated the use of sBCMA levels to track patients with myeloma who are receiving treatment. First, we showed that those with higher baseline sBCMA levels had worse outcomes. Second, changes in its levels correlated with changes in clinical status. Specifically, patients whose disease was worsening showed increasing amounts whereas those whose levels decreased showed improvements in their disease. We also showed that patients with levels in the normal range when they started new therapy had better outcomes. Furthermore, if patients started treatment with sBCMA levels that were above the normal range, they had better outcomes if their levels decreased to the normal range. Additionally, patients whose sBCMA increased by 25% or more from the start of their treatment during the first 12 weeks of treatment worsened faster. Importantly, while sBCMA levels correlated with changes in traditional blood markers for tracking myeloma, it identified changes in clinical status much more rapidly than those markers. Thus, disease that is worsening from a treatment could be found faster so patients could change therapies quickly. Lastly, for the growing numbers of patients with disease that is not measurable by the standard blood biomarkers, sBCMA can be used to monitor them effectively.

sBCMA in smoldering multiple myeloma and MGUS

Patients with a form of myeloma that does not initially require treatment is called smoldering multiple myeloma. These patients may progress to a point that they require treatment and we have shown that sBCMA levels predicted the likelihood of this occurring. Approximately 10 million Americans have a precursor form of myeloma called monoclonal gammopathy of undetermined significance (MGUS) with a higher risk of developing myeloma. We have shown that baseline sBCMA levels predicted the likelihood of that occurring and the survival of MGUS patients in general.

sBCMA in other diseases

We have also measured sBCMA in other related blood-based cancers including chronic lymphocytic leukemia (CLL), the most common type of leukemia. CLL patients showed elevated levels, and it predicted their outcomes and effectively monitored changes in their disease status similar to what we observed among patients with multiple myeloma. On the other hand, patients with primary immune deficient states that have reduced levels of immune cells show low levels of sBCMA and lower levels predict worse outcomes for these patients.

PEER-REVIEWED RESEARCH PAPERS- published since 2020

  • Chen H, Li M, Sanchez E, Soof CM, Bujarski S, Ng N, Cao J, Hekmati T, Zahab B, Nosrati J, Wen M, Wang CS, Tang G, Xu N, and Berenson JR, “JAK1/2 Pathway Inhibition Suppresses M2 Polarization and Overcomes Resistance of Myeloma to Lenalidomide by Reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 Expression,” Brit J Haematol. 188(2):283-294 (2020).
  • Moreau P, Stewart AKS, Dimopoulos M, Siegel D, Facon T, Berenson JR, Raje N, Berdeja JG, Orlowski RZ, Yang H, Ma H, Klippel Z, Zahlten-Kumeli A, Mezzi K, Iskander K, and Mateos VM, “Once-weekly (70 mg/m2) versus Twice-weekly (56 mg/m2) Dosing of Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma: A Post Hoc Analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 Trials,” Cancer Medicine. 9:2989-2996 (2020).
  • Henning C, Wang J, Swift R, Eades B, Spektor TM, and Berenson JR, “Removal of A Silicone Gel Breast Implant in a Multiple Myeloma Patient Improved Disease Status: A Case Report,” Case Reports in Oncology. 13(3):1103-1110 (2020).
  • Berenson JR, To J, Spektor T, Turner C, Sanchez A, Ghermezi M, Eades BR, Swift RA, Schwartz G, Eshaghian S, Stampleman L, Moss R, Lim S, and Vescio R, “A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Patients with Relapsed/Refractory Multiple Myeloma (RRMM),” Clinical Cancer Res. 26(10): 2346-2353 (2020).
  • Henning C, Meyers S, Eades B, Swift B, Bussell L, Spektor TM and Berenson JR, “The Efficacy of Topical Use Crisaborole 2% Ointment for Skin Lesions from Necrobiotic Xanthogranuloma Associated with Multiple Myeloma,” Clinical Lymphoma, Myeloma and Leukemia. 20(8): e492-e495 (2020).
  • Meyers S, Henning C, Swift R, Eades B, Spektor TM, and Berenson JR, “Treatment with Elotuzumab in Combination with Dexamethasone Achieves a Complete Remission in a Previously Treated Multiple Myeloma Patient: A Case Report,” Clinical Lymphoma, Myeloma and Leukemia. 20(11):e801-e804 (2020).
  • Regidor B, Swift R, Eades B, Emamy-Sadr M, Tarhini F, Spektor TM, and Berenson JR, “Frequent Occurrence of Hypophosphatemia among Multiple Myeloma Patients Treated with Elotuzumab: A Single Clinic Retrospective Study,” Annals of Hematol. 100(4):1079-1085 (2020).
  • Jew S, Chang T, Bujarski S, Spektor TM, Soof C, Chen H, Safaie T, Li M, Sanchez E, Wang C, Emamy‑Sadr M, Swift R, Rahbari A, Patil S, Souther E, and Berenson JR, “Normalization of Serum B‑cell Maturation Antigen Levels Predicts Overall Survival in Multiple Myeloma Patients Starting Treatment,” Brit J Haematol. 192:272-280 (2021).
  • Chen H, Li M, Sanchez E, Ng N, Yu E, Bujarski S, Yin Z, Wen M, Hekmati T, Field D, Wang J, Nassir I, Yu J, Huang J, Daniely D, Wang CS, Xu N, Spektor TMS, and Berenson JR, “Ruxolitinib Reverses Checkpoint Inhibition by Reducing PD-L1 Expression and Increases Anti-tumor Effects of T‑cells in Multiple Myeloma,” Brit J Haematol. 192:568-576 (2021).
  • Jew S, Bujarski S, Soof C, Chen H, Safaie T, Li M, Sanchez E, Wang C, Emamy-Sadr M, Swift R, Rahbari A, Patil S, Souther E, Spektor T, and Berenson JR, “Estimating a Normal Reference Range for Serum B-cell Maturation Antigen Levels for Multiple Myeloma Patients,” Brit J Haematol. 192(6):1064-1067 (2021).
  • Regidor B, Goldwater M-S, Wang J, Swift R, Eades B, Emamy-Sadr M, Eshagian S, Spektor TM, and Berenson JR, “Low Dose Venetoclax in Combination with Bortezomib, Daratumumab and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma Patients—A Single Center Retrospective Study,” Annals of Hematol. 100:2061-2070 (2021).
  • Bujarski S, Goldwater M, Regidor BS, Jew S, Swift RA, Eades BR, Emamy-Sadr M, Souther E, Li M, Wang C, Xu N, Chen H, Spektor TM, and Berenson JR, “Baseline Serum B-cell Maturation Levels Predict Time to Disease Progression for Patients with Smoldering Multiple Myeloma,” Eur J Haematol. 107:318-323 (2021).
  • Bujarski S, Udd K, Soof C, Chen H, Spektor T, Safaie T, Li M, Sanchez E, Stern J, Wang C, Xu N, Emamy-Sadr M, Swift R, Rahbari A, Patil S, Souther E, and Berenson JR, “Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status among Relapsed/Refractory Multiple Myeloma Patients undergoing New Treatments,” Targeted Oncology. 16:503-515 (2021).
  • Visram A, Soof C, Rajkumar SV, Kumar SK, Bujarski S, Spektor TM, Kyle RA, Berenson JR, and Dispenzieri A, “Serum BCMA Levels Predict Outcomes in MGUS and Smoldering Myeloma Patients,” Blood Cancer J. 11:120-126 (2021).
  • Stampfer SD, Goldwater M, Jew S, Bujarski S, Daniely D, Regidor B, Chen H, Xu N, Li M, Green T, Fung E, Aquino E, Swift R, Eshaghian S, Feinstein A, Spektor TM, and Berenson JR, “Response to mRNA Vaccination for COVID-19 among Patients with Multiple Myeloma,” Leukemia 35:3534-3541 (2021).
  • Bujarski S, Sutanto C, Spektor TM, To J, Swift RA, Green T, Eades BR, Emamy-Sadr M, Souther E, and Berenson JR, “Use of Serum B-cell Maturation Antigen (sBCMA) Levels to Predict Outcomes for Myeloma Patients Treated with Ruxolitinib, Lenalidomide and Methylprednisolone,” Hematological Oncology. 40(2):243-248 (2022).
  • Yashar D, Spektor TM, Martinez D, Sanchez AJ, Ghermezi M, Swift RA, Eades B, Schwartz G, Eshaghian S, Lim S, and Vescio R, and Berenson JR, “A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High-Risk Relapsed/Refractory Multiple Myeloma,” Leukemia and Lymphoma (published online).
  • Stampfer SD, Goldwater M-S, Bujarski S, Regidor B, Zhang W, Feinstein AJ, Jew S, Chen H, Xing N, Li M, Fung E, Aquino E, Swift R, Eshaghian S, Vail E, and Berenson JR, “Severe Breakthrough COVID-19 with a Heavily Mutated Variant in a Multiple Myeloma Patient 10 Weeks after Vaccination,” Clinical Infection in Practice (published online).
  • Zeidan, AM, Cook RJ, Bordoni R, Berenson JR, Edenfield WJ, Zhou G, Asatiani E, and Savona MR, “A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 and Itacitinib Alone or in Combination with Standard Therapies for Advanced Hematologic Malignancies,” Clinical Lymphoma, Myeloma and Leukemia (published online on January 20, 2022).
  • Daniely D, Forouzan E, Spektor TM, Cohen A, Bitran JD, Chen G, Moezi MM, Bessudo A, Coleman T, Hrom J, Eshaghian S, Swift RA, Eades BR, Lim S, and Berenson JR, “A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib,” Experimental Hematol. (published online on April 10, 2022).
  • Soof CM, Spektor TM, Parikh SA, Slager SL, Rabe KG, Call TG, Kednerian SS, Ding W, Muchtar E, Ghermezi M, Kay NE, and Berenson JR, “Serum B-Cell Maturation Antigen as a Prognostic Marker for Untreated Chronic Lymphocytic Leukemia,” Experimental Hematol. (in press).
  • Berenson JR, Kim C, Bujarski S, To J, Spektor TM, Martinez D, Turner C, Matthew Ghermezi, Eades BR, Swift RA, Schwartz G, Eshaghian S, Stampleman L, Moss RA, Lim S, MD, and Vescio R, “A Phase 1 Trial of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients,” Hematological Oncology. 40(5):906-913 (2022).
  • Afari J, Spektor TM, Turner C, Cohen A, Mackintosh R, Bessudo A, Jhangiani H, Gabrail N, Kubba S, Neidhart J, Swift RA, Eades BR, Kim C, Kim S, Vescio R, and Berenson JR, “Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen,” Experimental Hematology. 114:54-60 (2022).
  • Xu N, Yu E, Ng N, Li M, BS, Bujarski S, Yin Z, Hekmati T, Yu J, Daniely D, Wang CS, Chen H, and Berenson JR, “The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7H3 in Multiple Myeloma,” Hematological Oncology. 48:578-582 (2023).
  • Regidor BS, Siddiqi D, Beatty BM, Goldwater M-S, Jew S, Bujarski S, Swift R, Kim S, and Berenson JR. “Efficacy of Venetoclax Plus Anti-CD38 Monoclonal Antibody-Containing Therapies among t(11;14) positive Multiple Myeloma Patients Regardless of Timing of Prior Treatment with this Antibody,” Eur J. Hematol. 110(2):222-223 (2023).
  • Berenson JR, Martinez D, Safaie T, Boccia R, Yang H, Moezi M, Lim S, Schwartz G, Eshaghian S, Swift R, Eades BM, Bujarski S, Regidor B, Kim C, Kim S, and Vescio R, “Ruxolitinib and Methylprednisolone for Treatment of Patients with Relapsed/Refractory Multiple Myeloma,” British J. Haematol. 200(6):722-730 (2023).
  • Goldwater MS, Stampfer SD, Regidor BS, Bujarski S, Jew S, Chen H, Xu N, Li M, Dilawer S, Beatty B, Swift R, C, Kim S, and Berenson JR, “Third Dose of an mRNA COVID-19 Vaccine for Patients with Multiple Myeloma,” Clinical Infection in Practice. 17,100214 (2023).
  • Stampfer SS, Bujarski S, Goldwater M-S, Jew S, Regidor B, Chen H, Xu N, Li M, Fung E, Swift R, Beatty B, Eshaghian S, and Berenson JR, “Loss of Anti-Spike Antibodies Following mRNA Vaccination for COVID-19 among Patients with Multiple Myeloma,” Cancer Reports. 6(5):e1803 (2023).
  • Regidor BS, Scott Jew S, Goldwater M-S, Beatty BM, Bujarski S, Elsayed A, Danis R, Swift R, and Berenson JR, “Efficacy of Isatuximab in Combination with Steroids for the Treatment of Relapsed/Refractory Multiple Myeloma Patients Exhibiting Only Biochemical Progression—a Single Center Retrospective Study,” European J Hematol. 111(4):628-635 (2023).
  • Kim S and Berenson JR, “Predicting Outcomes and Monitoring Disease in Patients with Multiple Myeloma,” Clinical Advances in Hematol. and Oncol. 21:484-493 (2023).
  • Jew S, Bujarski S, Regidor B, Emamy-Sadr M, Swift R, Eades B, Eshaghian S, and Berenson JR, “Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real World Unselected Population of Newly Diagnosed Multiple Myeloma Patients,” Targeted Oncology. 18:735-747 (2023).
  • Del Dosso A, Tadevosyan E, and Berenson JR, “Preclinical and Clinical Evaluation of the Janus Kinase Inhibitor Ruxolitinib in Multiple Myeloma,” Oncotarget. 15:65-75 (2024).
  • Jew S, Goldwater M-S, Bujarski S, Regidor B, Emany-Sadr M, Swift R, Eades B, Said J, and Berenson JR, “The Incidence of Translocation t(11;14) among Patients with Multiple Myeloma in a Single Clinic,” Am J Clin Pathol. 161:16-23 (2024).
  • Berenson JR, Limon A, Rice S, Safaie T, Boccia R, Yang H, Moezi M, Lim S, Schwartz G, Eshaghian S, Brobeck M, Swift R, Eades BM, Bujarski S, Sebhat Y, Ray R, Kim S, Del Dosso A, and Vescio R, “A Phase 1 Trial Evaluating the Addition of Lenalidomide to Relapsed/Refractory Multiple Myeloma Patients Progressing on Ruxolitinib and Methylprednisolone,” Targeted Oncology. 19:343-357 (2024).
  • Danis R, Regidor B, Bujarski S, Scott Jew S, Goldwater M-S, Swift R, Eades B, Emamy-Sadr M, and Berenson JR, “Serum B-Cell Maturation Antigen Levels Reflect Disease Status in a Patient Who Developed Nonsecretory Multiple Myeloma: A Case Report,” Case Reports in Oncology. 17(1):747-752 (2024).
  • Yashar D, Bernard Regidor B, Marissa-Skye Goldwater M-S, Bujarski S, Del Dosso A, and Berenson JR, “Targeting B-Cell Maturation Antigen for Monitoring and Treatment of Relapsed/Refractory Multiple Myeloma Patients: A Comprehensive Review,” Therapeutic Advances in Hematology. https:// 15:2040620741275797 (2024).
  • ElSayed A, Mettias S, Danis R, Kim S, and Berenson JR, “Medical Writing Bias in Myeloma Clinical Research: A Comprehensive Analysis,” Perspectives in Clinical Research. 16:106-107 (2025).
  • Mettias S, Elsayed A, Moore J, and Berenson JR, “Multiple Myeloma: Improved Outcomes from a Rapidly Expanding Number of Therapeutic Options,” Targeted Oncology. 20:247-267 (2025).
  • Frenkel M, Alteber Z, Ning Xu N, Li M, Chen H, Hayoun D, Granit R, Cojocaru G, Berenson J, and Ophir E, “The Inhibitory Receptor PVRIG Is Dominantly Expressed in the Bone Marrow of Patients with Multiple Myeloma, and its Blockade Enhances T-Cell Engager’s Immune Activation,” Experimental Hematol. 143:104696 (2025).
  • Danis R, Bujarski S, Yashar D, Del Rosso A, Moore J, Mettias S, and Berenson JR, “Outcomes of Triple-Class Refractory Multiple Myeloma Patients at a Single Clinic: A Retrospective Study,” Leukemia Research. 151:107677.
  • Moore JT, Mettias SM, Swift R, Eades B, Eshaghian S, Schwartz G, and Berenson JR, “Clinical Outcomes for Unselected, Newly Diagnosed Multiple Myeloma Patients,” Haematologica. 110:2823-2826 (2025).
  • Goldwater M-S, Moore J, Sean Bujarski S, Danis R, Khan Z, Li M, Behare S, Swift R,  Emamy-Sadr M, Eades B, and Berenson JR, “Serum B-Cell Maturation Antigen as a Biomarker for Predicting Outcomes and Monitoring Patients with Waldenström’s Macroglobulinemia,” European J. Haematol. 116:31-36 (2026).
  • Mettias S, Cheung J, Moore J, and Berenson JR, “Treatment of a Previously Untreated Multiple Myeloma Patient with Daratumumab and Glucocorticosteroids Achieves a Complete Remission and Resolves Neutropenia: A Case Report,” Case Reports in Oncology. (in press).

RESEARCH PAPERS – Submitted for publication

  • Freytes CO, Stewart K, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, Stadtmauer E, Sahebi F, Tarantolo S, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Jacobs C, DiPersio J, Anderson K, Berenson JR, and Sing A, “CD34 Selection of Autologous Peripheral Blood Progenitor Cells Does Not Delay Immune Reconstitution or Increases the Incidence of Infections in Patients Transplanted for Multiple Myeloma,” (submitted).
  • Menke D, Chadburn A, Green E, Berenson JR, Said J, and Thome S, “Pathogenic Implications of Differences in Detection of HHV-8 Genome and HHV-8 vIL-6 Production in Castleman’s Disease: Implications for Pathogenesis,” (submitted).
  • Hortobagyi GN, Theriault RL, Berenson JR, Lipton A, Kowalski MO, and Seaman JJ, “Skeletal‑Related Events Associated with Metastatic Breast Cancer and Multiple Myeloma: A Comparative Analysis of Three Multicenter, Randomized Trials of Pamidronate Therapy,” (submitted).
  • Chen T, Ma P, Ravera C, Deckert F, Berenson JR, Goodin S, LoRusso P, Schran H, and Seaman J, “Plasma and Urine Pharmacokinetics of Zoledronic Acid in Cancer Patients with Bone Metastases by Noncompartmental and Compartmental Analyses,” (submitted).
  • Berenson JR, “Constitutively Active Nuclear Transcription Factor NF-B has Recently Emerged as a Major Underlying Factor in the Development,” (submitted).
  • Yeh H and Berenson J, “New Directions in the Treatment of Multiple Myeloma,” Medscape (submitted).
  • Baritaki S, Suzuki E, Umesawa K, Spandidos D, Berenson JR, Daniels TR, Penichet ML, Palladino M, and Bonavida B, “Reversal of Tumor Cell Resistance to TRAIL-Mediated Apoptosis by the Novel Proteasome Inhibitor, NPI-0052, via Inhibition of the Yin Yang 1 and Up-Regulation of DR5,” (submitted).
  • Bashey A, Pérez WS, Zhang M-J, Anderson KC, Ballen K, Berenson JR, Fonesca R, Fréytes CO, Gale RP, Gibson J, Giralt SA, Kyle RA, Lazarus HM, Maharaj D, McCarthy PL, Milone GA, Nimer S, Pavlovsky S, Reece DE, Schiller G, and Vesole DH, and Parameswaran H, “Syngenic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Comparison to Autologous Transplantation,” (submitted).
  • Cueto J, Waterman G, and Berenson J, “Achievement of Long-term Durable Remission with Single-Agent Zoledronic Acid for a Patient Active Multiple Myeloma,” (submitted).
  • Papanastassiou J, Anderson G, Berenson J, Chung G, Van Meirhaeghe J, Phillips F, Scott M, Small B, and Vrionis F, “Which Patients May Not Benefit from Vertebral Augmentation? Treatment Algorithm for Vertebral Compression Fractures,” (submitted).
  • Chen H, Zhang Y, Mao H, Zhao A, Du F, Gian J, Yang J, Wei J, Liu X, Sha Z Han Y, Situ W, Li C, Sheng L, Xu Y, Shou Z Vardanyan S, Bonavida B, and Berenson J, “Serum Autoantibodies Directed Against Moesin N1-297/C471-577 is Elevated in Immune Thrombocytopenia,” (submitted).
  • Halleluyan R, Keilty D, and Berenson JR, “Extramedullary Multiple Myeloma Involving the Pancreas: A Case Report,” (submitted).
  • Moore J, Tadevosyan E, Sebhat Y, Goldwater M-S, Cheung J, Swift R, Eades B, Schwartz G, Eshaghian S, Vescio R, and Berenson JR, “A Pilot Study of Selinexor, Methylprednisolone, and Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients,” (submitted).